Triple Combination Therapy in High Risk Crohn's Disease (CD)

NCT02764762 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Vedolizumab
DRUG: Adalimumab
DRUG: Methotrexate

Sponsor

Takeda